Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Peric, Barbara ^a   Zagar, Ivana ^a   Novakovic, Srdjan ^a   Zgajnar, Janez ^a   Hocevar, Marko ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S100B; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SKIN CANCER; SKIN METASTASIS; UPREGULATION; VISCERAL METASTASIS; WHOLE BODY TOMOGRAPHY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80052089427     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-328     Document Type: Article

References (20)

1. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004, 37(7):512-8. 10.1016/j.clinbiochem.2004.05.012, 15234232.
2. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. Biomarkers in melanoma. Ann Oncol 2009, 20(Suppl 6):vi8-13. 2712589, 19617299.
3. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34(4):357-64.
4. Petersson S, Shubbar E, Enerback L, Enerback C. Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res 2009, 19(4):215-25. 10.1097/CMR.0b013e32832c6358, 19521263.
5. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008, 123(10):2370-6. 10.1002/ijc.23794, 18752249.
6. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B, Kalff V. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 2008, 35(10):1786-95. 10.1007/s00259-008-0806-1, 18458901.
7. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009, 20(Suppl 6):vi14-vi21. 2712594, 19617293.
8. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37(1):181-200. 10.1007/s00259-009-1297-4, 2791475, 19915839.
9. Bonfrer JM, Korse CM. Monitoring malignant melanoma with the S-100B tumour marker. Recent Results Cancer Res 2001, 158:149-57.
10. Vrbic S, Filipovic S, Pejic I, Vrbic M, Filipovic A. Sensitivity, specificity, positive and negative predictive value of serum S-100 beta protein in patients with malignant melanoma. J BUON 2003, 8(2):139-41.
11. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006, 213(3):187-91. 10.1159/000095034, 17033166.
12. Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001, 18(2):109-20. 10.1385/MO:18:2:109, 11778756.
13. Banfalvi T, Udvarhelyi N, Orosz Z, Gergye M, Gilde K, Timar J. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology 2003, 64(4):374-9. 10.1159/000070296, 12759535.
14. Egberts F, Hitschler WN, Weichenthal M, Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009, 19(1):31-5. 10.1097/CMR.0b013e32831993cc, 19104452.
15. Strobel K, Skalsky J, Kalff V, Baumann K, Seifert B, Joller-Jemelka H, Dummer R, Steinert HC. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007, 34(9):1366-75. 10.1007/s00259-007-0403-8, 17390135.
16. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005, 20(1):34-42.
17. Vitzthum J, Dorr HD, Meineke V. Ultraviolet B exposure could influence the interpretation of serum S100beta levels in patients with malignant melanoma. Br J Dermatol 2007, 156(4):772-3. 10.1111/j.1365-2133.2006.07737.x, 17493078.
18. Aukema TS, Olmos RA, Korse CM, Kroon BB, Wouters MW, Vogel WV, Bonfrer JM, Nieweg OE. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010, 17(6):1657-61. 10.1245/s10434-010-0963-x, 20151211.
19. Leiter U, Marghoob AA, Lasithiotakis K, Eigentler TK, Meier F, Meisner C, Garbe C. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009, 19(1):50-7. 10.1097/CMR.0b013e32831bc41c, 19430406.
20. Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Res 2010, 20(3):240-6.